To better predict the onset of Parkinson's disease and to accelerate the development of better treatments, this is the main goal of Biospective Inc. in Quebec and inviCRO LLC in Massachusetts, two service companies working in the field of medical imaging that will collaborate for the first time thanks to the funding of $ 500,000 which Québec Consortium for Drug Discovery (CQDM) and the Massachusetts Life Sciences Center (MLSC) announced today at BIO-Europe in Turin.
The two business partners will match these contributions in either cash or in-kind taking to more than one million dollars the value of this project. The funding of this first collaboration with Massachusetts was made possible thanks to the financial support of the Quebec Governement’s Ministère de l’Enseignement supérieur, de la Recherche, de la Science et de la Technologie (MESRST).
"We are very pleased with this first achievement with our partner, the MLSC, which demonstrates our commitment to develop fruitful collaborations between researchers in Quebec and Massachusetts, a very fertile area in the life sciences, and I thank the Quebec Government for making this possible. This new project will also generate added value to the pharmaceutical industry which is looking to develop new treatments for Parkinson's disease, a complex and still poorly understood disease," said Diane Gosselin, Ph.D., President and CEO of CQDM.
"The partnership with inviCRO LLC and Biospective will help bring new health technologies to the market along with economic benefits for both Quebec and Massachusetts,” said Susan Windham-Bannister, Ph.D., President and CEO of the MLSC.
"Biospective is excited to partner with CQDM and inviCRO on this project. We anticipate advancing our understanding of the complex pathophysiology of Parkinson’s disease, as well as facilitating the assessment of efficacy of novel, disease-modifying therapeutic agents through the development of rigorously validated, state-of-the-art, imaging biomarkers. The innovative platform that we plan to develop will allow us to expand our range of services, and establish a dominant position in the market for preclinical Parkinson's disease studies," said Barry Bedell, M.D., Ph.D., COO and CSO of Biospective.
The Chief Scientist of Quebec, Rémi Quirion, Ph.D., welcomes this first international research collaboration with Massachusetts. "Such collaboration is particularly relevant because it aims at providing innovative solutions in the treatment of neurodegenerative diseases such as Parkinson's, a
life sciences field which mobilizes researchers from Quebec and their international collaborators. This project might also lead to concrete economic benefits for the population," said the Chief Scientist.